271 related articles for article (PubMed ID: 33820396)
1. Characteristics of Immune-Related Thyroid Adverse Events in Patients Treated with PD-1/PD-L1 Inhibitors.
Yoon JH; Hong AR; Kim HK; Kang HC
Endocrinol Metab (Seoul); 2021 Apr; 36(2):413-423. PubMed ID: 33820396
[TBL] [Abstract][Full Text] [Related]
2. Immune Checkpoint Inhibitor-induced Thyroid Dysfunction Is Associated with Higher Body Mass Index.
Pollack R; Ashash A; Cahn A; Rottenberg Y; Stern H; Dresner-Pollak R
J Clin Endocrinol Metab; 2020 Oct; 105(10):. PubMed ID: 32668461
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients.
Kotwal A; Kottschade L; Ryder M
Thyroid; 2020 Feb; 30(2):177-184. PubMed ID: 31813343
[No Abstract] [Full Text] [Related]
4. Tumor PD-L1 expression and molecular profiling are not associated with immune checkpoint inhibitor-induced thyroid dysfunction in advanced NSCLC patients.
Horesh A; Pollack R; Nechushtan H; Dresner-Pollak R; Neuman T
Pathol Oncol Res; 2023; 29():1610951. PubMed ID: 37139142
[No Abstract] [Full Text] [Related]
5. Thyroid function abnormality induced by PD-1 inhibitors have a positive impact on survival in patients with non-small cell lung cancer.
Zhou Y; Xia R; Xiao H; Pu D; Long Y; Ding Z; Liu J; Ma X
Int Immunopharmacol; 2021 Feb; 91():107296. PubMed ID: 33360368
[TBL] [Abstract][Full Text] [Related]
6. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
Gu YC; Liu Y; Xie C; Cao BS
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
[TBL] [Abstract][Full Text] [Related]
7. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment.
Muir CA; Clifton-Bligh RJ; Long GV; Scolyer RA; Lo SN; Carlino MS; Tsang VHM; Menzies AM
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3704-e3713. PubMed ID: 33878162
[TBL] [Abstract][Full Text] [Related]
8. Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand.
Patrinely JR; Young AC; Quach H; Williams GR; Ye F; Fan R; Horn L; Beckermann KE; Gillaspie EA; Sosman JA; Friedman DL; Moslehi JJ; Johnson DB
Eur J Cancer; 2020 Aug; 135():211-220. PubMed ID: 32599411
[TBL] [Abstract][Full Text] [Related]
9. Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events.
Cortellini A; Bersanelli M; Santini D; Buti S; Tiseo M; Cannita K; Perrone F; Giusti R; De Tursi M; Zoratto F; Marconcini R; Russano M; Zeppola T; Anesi C; Filetti M; Marchetti P; Botticelli A; Gelibter A; De Galitiis F; Vitale MG; Rastelli F; Tudini M; Silva RR; Atzori F; Chiari R; Ricciuti B; De Giglio A; Migliorino MR; Mallardo D; Vanella V; Mosillo C; Bracarda S; Rinaldi S; Berardi R; Natoli C; Ficorella C; Porzio G; Ascierto PA
Eur J Cancer; 2020 Mar; 128():17-26. PubMed ID: 32109847
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint inhibitor-related thyroid dysfunction.
Iwama S; Kobayashi T; Yasuda Y; Arima H
Best Pract Res Clin Endocrinol Metab; 2022 May; 36(3):101660. PubMed ID: 35501263
[TBL] [Abstract][Full Text] [Related]
11. Hypothyroidism in Head and Neck Squamous Cell Carcinoma Patients Receiving Radiotherapy With or Without Immune Checkpoint Inhibitors.
Leddon JL; Chirra M; Frankart AJ; Agrawal A; Roof L; Trotier D; Shaikh H; Stone T; Jandarov R; Takiar V; Wise-Draper TM
Laryngoscope; 2021 Jul; 131(7):E2413-E2419. PubMed ID: 33609046
[TBL] [Abstract][Full Text] [Related]
12. Immune-related adverse events with PD-1 versus PD-L1 inhibitors: a meta-analysis of 8730 patients from clinical trials.
Sonpavde GP; Grivas P; Lin Y; Hennessy D; Hunt JD
Future Oncol; 2021 Jul; 17(19):2545-2558. PubMed ID: 33783228
[No Abstract] [Full Text] [Related]
13. New and Worsening Long-term Immune-Related Adverse Events with PD-1/PD-L1 Pathway Agents in Patients with Cancer.
Hall KH; Liu Y; Jiang C; Harvey RD
Pharmacotherapy; 2020 Feb; 40(2):133-141. PubMed ID: 31863604
[TBL] [Abstract][Full Text] [Related]
14. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
15. Immune-related thyroid dysfunctions during anti PD-1/PD-L1 inhibitors: new evidence from a single centre experience.
Nervo A; Ferrari M; Gruosso G; Migliore E; Basile S; D'Angelo V; Roux A; Piovesan A; Arvat E
Clin Exp Med; 2023 Dec; 23(8):4817-4824. PubMed ID: 37103651
[TBL] [Abstract][Full Text] [Related]
16. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
Sun X; Roudi R; Dai T; Chen S; Fan B; Li H; Zhou Y; Zhou M; Zhu B; Yin C; Li B; Li X
BMC Cancer; 2019 Jun; 19(1):558. PubMed ID: 31182061
[TBL] [Abstract][Full Text] [Related]
17. Effectivity and safety of PD-1/PD-L1 inhibitors for different level of PD-L1-positive, advanced NSCLC: A meta-analysis of 4939 patients from randomized controlled trials.
Shi Y; Duan J; Guan Q; Xue P; Zheng Y
Int Immunopharmacol; 2020 Jul; 84():106452. PubMed ID: 32339922
[TBL] [Abstract][Full Text] [Related]
18. Prospective evaluation of the prognostic value of immune-related adverse events in patients with non-melanoma solid tumour treated with PD-1/PD-L1 inhibitors alone and in combination with radiotherapy.
Schweizer C; Schubert P; Rutzner S; Eckstein M; Haderlein M; Lettmaier S; Semrau S; Gostian AO; Frey B; Gaipl US; Zhou JG; Fietkau R; Hecht M
Eur J Cancer; 2020 Nov; 140():55-62. PubMed ID: 33045663
[TBL] [Abstract][Full Text] [Related]
19. Thyroid dysfunction after immune checkpoint inhibitor treatment in a single-center Chinese cohort: a retrospective study.
Wu L; Xu Y; Wang X; Cheng X; Zhang Y; Wang Y; Fan X; Zhao H; Liu H; Chai X; Zhang L; Wang M; Li N; Pan H; Lian X
Endocrine; 2023 Jul; 81(1):123-133. PubMed ID: 36867366
[TBL] [Abstract][Full Text] [Related]
20. Safety and Efficacy of PD-1/PD-L1 Inhibitors in Cancer Patients With Preexisting Autoantibodies.
Tang H; Geng R; Xu X; Wang Y; Zhou J; Zhang S; Zhao L; Guan M; Bai C
Front Immunol; 2022; 13():893179. PubMed ID: 35651612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
